Data Sheet ABILIFYTM - Medsafe
NZ_DS_Abilify_V2.1_ August2016 - 1 - Data Sheet for ABILIFYTM aripiprazole Tablets: 5 mg 10 mg, 15 mg, 20 mg & 30 mg NAME OF THE MEDICINE Aripiprazole.
Download Data Sheet ABILIFYTM - Medsafe
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
統合失調症について - www-yaku.meijo-u.ac.jp
www-yaku.meijo-u.ac.jpAmerican Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders fourth edition text revision DSM-Ⅳ-TR, American Psychiatric Association, 2000
表 第 章のまとめ - asas.or.jp
www.asas.or.jp95 ドン(2~6mg)が5 試験4, 7, 14-16)あり,Positive and Negative Syndrome Scale Excited Component(PANSS-EC), Brief Psychiatric Rating Scale(BPRS)などの …
Scale, Brief, Ratings, Psychiatric, Bprs, Brief psychiatric rating scale bprs
Cuestionario para Escolares y Adolescentes ...
www.medigraphic.comCuestionario para Escolares y Adolescentes Latinoamericanos con TDAH Vol. 32, Supl. 1, 2009 S57 Escalas dimensionales Inventario de Síntomas para Niños y …
Para, Escolares, Adolescentes, Cuestionario para escolares y adolescentes, Cuestionario
DCPAR for Elvanse 30mg 50 mg and 70 mg hard …
www.mhra.gov.ukPublic Assessment Report Decentralised Procedure Elvanse 30 mg, 50 mg and 70 mg capsules, hard Lisdexamfetamine dimesylate UK/H/3326/001-03/DC
Crisis Monitor in de spoedeisende psychiatrie - VVP …
www.vvp-online.beCrisis Monitor in de spoedeisende psychiatrie Dr. Roland van de Sande (onderzoeker / hoofddocent) Edwin Hellendoorn, M.A (coördinerend behandelaar)